16 Result(s)

Article

Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks

Jonathan D. Diedrich, Qian Dong, Daniel C. Ferguson, Brennan P. Bergeron… in Leukemia (2024)

Article

Is there really an accelerated phase of chronic myeloid leukaemia?

Robert Peter Gale, Qian Jiang, Jane F. Apperley, Andreas Hochhaus in Leukemia (2024)

Article

Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients

Olga Sala-Torra, Lan Beppu, Qian Wu, Emily Welch, Erwin Berthier… in Leukemia (2024)

Article

NPM1 mutation reprograms leukemic transcription network via resha** TAD topology

C-terminal mutation of Nucleophosmin 1 (NPM1^C+) was thought to be a primary driving event in acute myeloid leukemia (AML) that reprograms leukemic-associated transcription programs to transform hematopoietic stem...

Qian Lai, Karina Hamamoto, Huacheng Luo, Zachary Zaroogian, Caixian Zhou… in Leukemia (2023)

Article

Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia

Chemoresistance and relapse are the leading cause of AML-related deaths. Utilizing single-cell RNA sequencing (scRNA-seq), we dissected the cellular states of bone marrow samples from primary refractory or sho...

Kening Li, Yuxin Du, Yun Cai, Wenjie Liu, Yan Lv, Bin Huang, Lishen Zhang… in Leukemia (2023)

Article

Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia

Glucocorticoids (GCs) are a mainstay of contemporary, multidrug chemotherapy in the treatment of childhood acute lymphoblastic leukemia (ALL), and resistance to GCs remains a major clinical concern. Resistance...

Brennan P. Bergeron, Jonathan D. Diedrich, Yang Zhang, Kelly R. Barnett… in Leukemia (2022)

Article

Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?

Data from 1661 consecutive subjects with chronic-phase chronic myeloid leukemia (CML) receiving initial imatinib (n = 1379) or a 2^nd-generation tyrosine-kinase inhibitor (2G-TKI; n = 282) were interrogated to det...

**ao-Shuai Zhang, Robert Peter Gale, **ao-Jun Huang, Qian Jiang in Leukemia (2022)

Article

Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study

Yong Yang, Ying Wang, **n Liu, **a He, Li-Ling Zhang, Gang Wu, Bao-Lin Qu… in Leukemia (2021)

Article

Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study

Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of extranodal NK/T-cell lymphoma (ENKTCL) in the modern era. We aim to analyze progression-free survival at 24 ...

Yong Yang, Ying Wang, **n Liu, **a He, Li-Ling Zhang, Gang Wu, Bao-Lin Qu… in Leukemia (2021)

Article

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in...

Tingyu Wen, **song Wang, Yuankai Shi, Haili Qian, Peng Liu in Leukemia (2021)

Article

Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making

Derived from our original nomogram study by using the risk variables from multivariable analyses in the derivation cohort of 1383 patients with extranodal NK/T-cell lymphoma, nasal-type (ENKTCL) who were mostl...

Si-Ye Chen, Yong Yang, Shu-Nan Qi, Ying Wang, Chen Hu, **a He, Li-Ling Zhang… in Leukemia (2021)

Article

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this t...

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu… in Leukemia (2020)

Article

COVID-19 in persons with chronic myeloid leukaemia

We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of ...

Weiming Li, Danyu Wang, **gming Guo, Guolin Yuan, Zhuangzhi Yang… in Leukemia (2020)

Article

Do persons with chronic myeloid leukaemia have normal or near normal survival?

Tomas Radivoyevitch, Davis Weaver, Brian Hobbs, Jaroslaw P. Maciejewski… in Leukemia (2020)

Article

A novel Lin−CD34+CD38− integrin α2− bipotential megakaryocyte–erythrocyte progenitor population in the human bone marrow

W M Wong, M Dolinska, M Sigvardsson, M Ekblom, H Qian in Leukemia (2016)

Article

Erratum: Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma

Correction to: Leukemia (2012) 26, 2114–2123; doi:10.1038/leu.2012.71 Since the publication of this article, the authors have identified an error contained within Figure 1, namely that it contained the same im...

J Yang, J He, J Wang, Y Cao, J Ling, J Qian, Y Lu, H Li, Y Zheng, Y Lan, S Hong… in Leukemia (2015)